- Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models.
Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine (2014-12-06)
Priscilla B Pujatti, Julie M Foster, Ciara Finucane, Chantelle D Hudson, Jerome C Burnet, Kerly F M Pasqualoto, Jair Mengatti, Stephen J Mather, Elaine B de Araújo, Jane K Sosabowski
PMID25479439
ABSTRACT
We evaluated and compared a new bombesin analog [Tyr-Gly5, Nle(14)]-BBN(6-14) conjugated to DOTA or DTPA and radiolabeled with In-111 in low and high GRPR expressing tumor models. Both peptides were radiolabeled with high radiochemical purity and specific activity. In vitro assays on T-47D, LNCaP and PC-3 cells showed that the affinity of peptides is similar and a higher binding and internalization of DOTA-peptide to PC-3 cells was observed. Both peptides could target PC-3 and LNCaP tumors in vivo and both tumor types could be visualized by microSPECT/CT.
MATERIALS
Product Number
Brand
Product Description
Supelco
Sodium dodecyl sulfate, dust-free pellets, suitable for electrophoresis, Molecular Biology, ≥99.0% (GC)
Sigma-Aldrich
Sodium dodecyl sulfate, tested according to NF, mixture of sodium alkyl sulfates consisting mainly of sodium dodecyl sulfate
Sigma-Aldrich
Sodium dodecyl sulfate, BioReagent, suitable for electrophoresis, Molecular Biology, ≥98.5% (GC)